2/2
© Reuters FILE PHOTO: Needles with needles are seen in front of the iconic Modelina logo in this Nov. 27, 2021, picture. REUTERS/Dado Ruvic/Illustration
2/2
© Reuters FILE PHOTO: Needles with needles are seen in front of the iconic Modelina logo in this Nov. 27, 2021, picture. REUTERS/Dado Ruvic/Illustration
2/2
TOKYO (Reuters) – Modern (NASDAQ: ) Inc believed that BioNTech SE (NASDAQ: ) had used its intellectual property to develop a rival vaccine since the beginning of the COVID-19 pandemic, CEO Stefan Bansel said Wednesday.
Moderia filed suit against BioNTech and its partner. Pfizer Inc (NYSE: ) filed for patent infringement on the development of the first Covid-19 vaccine approved in the United States last month.
Speaking in Tokyo, Bansel said Moderia is considering building facilities in Japan to manufacture mRNA-derived products.